eprintid: 10131316 rev_number: 24 eprint_status: archive userid: 608 dir: disk0/10/13/13/16 datestamp: 2021-07-15 12:33:11 lastmod: 2022-08-18 08:29:32 status_changed: 2021-07-15 12:33:11 type: article metadata_visibility: show creators_name: Hussein, M creators_name: Alzoubaidi, D creators_name: O'Donnell, M creators_name: de la Serna, A creators_name: Bassett, P creators_name: Varbobitis, I creators_name: Hengehold, T creators_name: Ortiz Fernandez-Sordo, J creators_name: Rey, JW creators_name: Hayee, B creators_name: Despott, EJ creators_name: Murino, A creators_name: Graham, D creators_name: Latorre, M creators_name: Moreea, S creators_name: Boger, P creators_name: Dunn, J creators_name: Mainie, I creators_name: Mullady, D creators_name: Early, D creators_name: Ragunath, K creators_name: Anderson, J creators_name: Bhandari, P creators_name: Goetz, M creators_name: Kiesslich, R creators_name: Coron, E creators_name: Rodriguez de Santiago, E creators_name: Gonda, T creators_name: Gross, SA creators_name: Lovat, LB creators_name: Haidry, R title: Hemostatic powder TC-325 treatment of malignancy-related upper gastrointestinal bleeds: International registry outcomes ispublished: inpress subjects: UCH divisions: UCL divisions: B02 divisions: C10 divisions: D17 divisions: D16 divisions: G88 keywords: endoscopy, malignancy, non-variceal, upper GI, upper gastrointestinal bleeding note: © 2021 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. abstract: BACKGROUND AND AIM: Upper gastrointestinal tumors account for 5% of upper gastrointestinal bleeds. These patients are challenging to treat due to the diffuse nature of the neoplastic bleeding lesions, high rebleeding rates, and significant transfusion requirements. TC-325 (Cook Medical, North Carolina, USA) is a hemostatic powder for gastrointestinal bleeding. The aim of this study was to examine the outcomes of upper gastrointestinal bleeds secondary to tumors treated with Hemospray therapy. METHODS: Data were prospectively collected on the use of Hemospray from 17 centers. Hemospray was used during emergency endoscopy for upper gastrointestinal bleeds secondary to tumors at the discretion of the endoscopist as a monotherapy, dual therapy with standard hemostatic techniques, or rescue therapy. RESULTS: One hundred and five patients with upper gastrointestinal bleeds secondary to tumors were recruited. The median Blatchford score at baseline was 10 (interquartile range [IQR], 7-12). The median Rockall score was 8 (IQR, 7-9). Immediate hemostasis was achieved in 102/105 (97%) patients, 15% of patients had a 30-day rebleed, 20% of patients died within 30 days (all-cause mortality). There was a significant improvement in transfusion requirements following treatment (P < 0.001) when comparing the number of units transfused 3 weeks before and after treatment. The mean reduction was one unit per patient. CONCLUSIONS: Hemospray achieved high rates of immediate hemostasis, with comparable rebleed rates following treatment of tumor-related upper gastrointestinal bleeds. Hemospray helped in improving transfusion requirements in these patients. This allows for patient stabilization and bridges towards definitive surgery or radiotherapy to treat the underlying tumor. date: 2021-06-15 date_type: published official_url: https://doi.org/10.1111/jgh.15579 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1875542 doi: 10.1111/jgh.15579 lyricists_name: Alzoubaidi, Durayd lyricists_name: Lovat, Laurence lyricists_id: DALZO44 lyricists_id: LBLOV52 actors_name: Barczynska, Patrycja actors_id: PBARC91 actors_role: owner full_text_status: public publication: Journal of Gastroenterology and Hepatology event_location: Australia citation: Hussein, M; Alzoubaidi, D; O'Donnell, M; de la Serna, A; Bassett, P; Varbobitis, I; Hengehold, T; ... Haidry, R; + view all <#> Hussein, M; Alzoubaidi, D; O'Donnell, M; de la Serna, A; Bassett, P; Varbobitis, I; Hengehold, T; Ortiz Fernandez-Sordo, J; Rey, JW; Hayee, B; Despott, EJ; Murino, A; Graham, D; Latorre, M; Moreea, S; Boger, P; Dunn, J; Mainie, I; Mullady, D; Early, D; Ragunath, K; Anderson, J; Bhandari, P; Goetz, M; Kiesslich, R; Coron, E; Rodriguez de Santiago, E; Gonda, T; Gross, SA; Lovat, LB; Haidry, R; - view fewer <#> (2021) Hemostatic powder TC-325 treatment of malignancy-related upper gastrointestinal bleeds: International registry outcomes. Journal of Gastroenterology and Hepatology 10.1111/jgh.15579 <https://doi.org/10.1111/jgh.15579>. (In press). Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10131316/1/Lovat_jgh.15579.pdf